News

Sir Nigel Shadbolt joins BenevolentAI as a non-executive director

We are thrilled to announce Sir Nigel Shadbolt has joined our Board of Directors as a non-executive.

At BenevolentAI, we build technology to advance scientific discovery and ultimately to make a positive impact on patient outcomes. We recognise that delivering on our mission demands collaboration with world-leading experts and we could not wish for more wisdom, knowledge and expertise than that of Sir Nigel Shadbolt. 

Sir Nigel is a visionary and pioneer in AI and computer science with an academic career reaching back to 1978, when he began a PhD at Edinburgh University’s Department of AI. During his academic career he established internationally recognised research groups at the Universities of Nottingham, Southampton and Oxford. Sir Nigel is now Principal of Jesus College, Oxford and a Professor in the Department of Computer Science at the University of Oxford where he researches and leads a group on human-centred computing and AI. In 2009, he was appointed as Information Advisor to the UK government and helped establish the UK as a leading force in the publication and use of open data. He is Chairman of the Open Data Institute, which he founded in 2012 with Sir Tim Berners Lee with the purpose of building an open, trustworthy data ecosystem. He was one of the originators of the interdisciplinary field of Web Science, the study of the large-scale socio-technical system that is the World Wide Web. He is a Director and Trustee of the Web Science Trust, which promotes policy, research and teaching in this emerging area.  

Sir Nigel’s research into the Semantic Web forged the way for new companies, such as Garlik, acquired by Experian in 2011. He continues to research and advocates for open data – identifying where it can be used to promote economic and social value. Recent work on the theory and practice of ‘social machines’ is leading the way in integrating humans and computers in novel and unanticipated ways so as to augment our problem solving capabilities. As an interdisciplinary researcher, policy expert and scientific commentator, Sir Nigel brings with him an unrivalled depth of experience and technical background in tech, AI and data.

Our core purpose at Benevolent is summarised by our mantra, ‘because it matters’. Behind this, sits a team of passionate and dedicated people whose curiosity, humility and openness to learning are what will allow us to progress on the complex problems we are tackling, and ultimately, will be what leads us to discover new vital treatments for patients. We are excited to integrate Sir Nigel’s expertise and knowledge into our board and to count him as part of this team and mission.


Sir Nigel Shadbolt commented:

“At its best AI augments human ingenuity and creativity. BenevolentAI combines human expertise with the latest AI and machine learning methods to provide extraordinary potential for drug design and discovery. I am delighted to be a part of their journey.”

Joanna Shields, CEO
More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022